Vladimir Suàrez - Gironzini

Radiation/Clinical Oncologist

[Mike Chao @drmikechao]

Proximity of large bowel would have made this renal SABR tricky. Hyaluronic Acid HA to the rescue with retroperitoneal spacing to facilitate stressless SABR. Life is indeed easier with HA. #radonc @Barrigel_spacer

[Elena Moreno-Olmedo @elenmol2]

📰Thrilled to share our review about grey zones in BCR after RP.
🔎Seeking balance between delaying M1 onset (ADT intensification) but avoiding overtreatment of an indolent disease (right timing?)
🧬Biomarkers&Genomic classifier’ ll improve BCR characterisation and pt selection.

[Elena Moreno-Olmedo @elenmol2]

Thanks for sharing @urotoday @RKSayyid . It has been a pleasure to present our outcomes at #ASTRO23 @ASTRO_org

[Cancers MDPI @Cancers_MDPI]

🔆An analysis of the PACE-B population demonstrates that patients who experience acute urinary or bowel toxicity are more prone to develop late toxicity following prostate SBRT🔆

Access the full paper here 👉 https://t.co/mQWKdvaLFL
👏by Ragu Ratnakumaran et al. @royalmarsdenNHS

[Radiotherapy & Oncology @RO_GreenJournal]

New article (vol 186)

Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer
G. Nagore et al.

https://t.co/HYeQ9fc3wX

https://t.co/yYRyowzbyU

[Elena Moreno-Olmedo @elenmol2]

Now yes! The complete article is out! https://t.co/sr8CPAtRcd

[Gustavo @gusviani]

🎙 2 fractions HDR-BT monotherapy is a highly curative radiation technique for LR/IR #prostatecancer❗️@oncoalert @RadiotherapyOn1
📌Prospective study 120 👥➡️ HDR BT monotherapy in 2Fx in one day
- 🚹 84 LR/ 35 IR Pca
- 💊 31% ADT
📊RESULT
👉Median FU:123 mo
👉Actuarial rates: 93.3% bNED/86.7% OS/95.2% LC/96.1% MFS
👉Median ⌛to PSA nadir 80.5mo
👉PSA Nadir ≤ 0.20 ng/mL ➡️10-ybNED 96.9% ✖️40% for those who didn't reach
https://t.co/oJMdvjA2Dw

[Ricardo Soares @soares_uro]

Metastasis-directed therapy (MDT) in prostate cancer with SABR/SBRT and sLND:
- postpone need for ADT
- improved PFS
- one study with improved OS with SOC + SABR
@jeffkarnesMD @MayoUrology #AUA23

[Benjamin Rich @BenRichMD]

RTOG 0815 now out in JCO.

Dose-escalated RT for intermediate risk prostate cancer w/wo short-term ADT.

Median follow-up 6.3 years.

ADT reduced PSA failure, DM, PCSM, salvage therapy use.

No OS benefit, but unlikely with ~6 years FU.

#radonc #pcsm

https://t.co/o1uTKhjvcB

[Alison Tree 💙 @alison_tree]

@agomeziturriaga @piet_ost @_ShankarSiva @SbrtSean @DrMHofman @roodvdb @joniau @AlbertoBossial @fontev1 @PCaParker @DrSpratticus Another option is SBRT 30/5, maybe up to 34/5. All ablative options likely offer similar PSA control so it’s about side effect profile. I agree that short course ADT sensible. We need more data on this scenario though!

[GenesisCare España @GenesisCareES]

#RAGM2023 | Los doctores Neal Shore, Nat Lenzo, José Luis Pérez Gracia y @Vladisu nos compartieron sus conocimientos y experiencia en la mesa de #CáncerDePróstata. Aprendimos que 👇

[Shankar Siva @_ShankarSiva]

🔥🔥 primary endpoint analysis from @nickva1 of PACE-A; SBRT versus robotic prostatectomy for #prostatecancer RCT. Co-primary toxicity endpoints (continence/bowel) #GU23 @ASCO @OncoAlert @NHSuk. N=123, SBRT had ⬇️ pad use ⬇️ sexual dysfunction but ⬆️ bowel bother. All low grade.

[Nicholas van As @nickva1]

Arrived in San Fran! Looking forward to presenting the #PACE-A results tomorrow at #GU23 @alison_tree @SbrtSean @DrAndrewLoblaw

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence … https://t.co/mwkcxnliI8

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. https://t.co/gf4JKJLeFS

[JAMA Oncology @JAMAOnc]

Multicenter randomized clin trial in prostate cancer tested presence or absence of hyaluronic acid rectal spacer before receiving hypofractionated radiation, showed acute grade >2 GI toxicity in 2.9% of pts w/spacer vs. 13.8% in control group #PCSM #RadOnc https://t.co/eTifx0b1x2

[Dr. Andrew Loblaw @DrAndrewLoblaw]

@weeloonong leads our #2SMART medium term outcomes: 26Gy in 2 + microboost (up to 32/2). 2mm margins enabled by #GU-Lok

Feasible and well tolerated! Comparison to 26/2 w/o microboost coming soon

@RadiotherapyOn1 #greenjournal
Link here: https://t.co/gmthbPsYD3

[GenesisCareUK @GenesisCare]

A new 5-year outcome study from IROCK shows single-fraction #SABR for #renal cell carcinoma had a local control rate of 94.5% and a distant control rate of 87.3% plus no local failure was observed after in 86% of patients. Read more here 👉 https://t.co/pjKtg5yu0y

[Barrigel @Barrigel_spacer]

Thank you Dr. @elenmol2 for sharing your experience with #Barrigel and for reminding all of us on the importance of delivering the best possible outcomes for patients on this #WorldCancerDay.

[Alison Tree 💙 @alison_tree]

PACE-B 2 year paper finally out!
https://t.co/mERz2ox8TM Tweetorial coming shortly, but firstly massive thanks to @nickva1 @EmmaHall71 @royalmarsdenNHS @royalmarsden @Accuray @VarianMedSys @ICR_CTSU @ProstateUK and many more, for support of the PACE umbrella